

# **The Global Prevalence of Hepatitis E Virus Infection and Susceptibility: A Systematic Review**

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**

# **The Global Prevalence of Hepatitis E Virus Infection and Susceptibility: A Systematic Review**

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**

---

**The Department of Immunization, Vaccines and Biologicals  
thanks the donors whose unspecified financial support  
has made the production of this document possible.**

This report was produced for the Expanded Programme on Immunization  
of the Department of Immunization, Vaccines and Biologicals by:

Rakesh Aggarwal, MD, DM, MSc (Epidemiology)  
Department of Gastroenterology  
Sanjay Gandhi Postgraduate Institute of Medical Sciences  
Lucknow, India

*Ordering code: WHO/IVB/10.14*

*Printed: December 2010*

**This publication is available on the Internet at:**

[www.who.int/vaccines-documents/](http://www.who.int/vaccines-documents/)

**Copies of this document as well as additional materials on  
immunization, vaccines and biologicals may be requested from:**

World Health Organization  
Department of Immunization, Vaccines and Biologicals  
CH-1211 Geneva 27, Switzerland

• *Fax:* + 41 22 791 4227 • *Email:* [vaccines@who.int](mailto:vaccines@who.int) •

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

**Printed by the WHO Document Production Services, Geneva, Switzerland**

---

# Contents

<i>Acknowledgements</i> .....	<i>v</i>
<b>Background</b> .....	<b>1</b>
<b>Methods</b> .....	<b>8</b>
<b>Regional reports</b> .....	<b>12</b>
Asia-pacific, high income .....	13
Central Asia.....	23
Asia, East .....	28
Asia, South.....	36
Asia, Southeast .....	55
Australasia .....	63
Caribbean .....	66
Europe, Central.....	71
Europe, Eastern.....	76
Europe, Western.....	80
Latin America, Andean .....	95
Latin America, Central.....	98
Latin America, Southern .....	103
Latin America, Tropical .....	107
North Africa / Middle East.....	112
North America, High Income .....	124
Oceania .....	128
Sub-Saharan Africa, Central .....	131
Sub-Saharan Africa, East .....	133
Sub-Saharan Africa, Southern.....	141
Sub-Saharan Africa, West .....	144
<b>Appendix: Abstracts</b> .....	<b>150</b>
Asia-Pacific, High Income .....	151
Central Asia .....	164
Asia, East .....	168
Asia, South.....	180
Asia, Southeast .....	209
Australasia .....	218

---

Caribbean .....	221
Europe, central.....	223
Europe, Eastern.....	227
Europe, Western.....	231
Latin America, Andean .....	250
Latin America, Central.....	253
Latin America, Southern .....	256
Latin America, Tropical.....	260
North Africa / Middle East .....	265
North America, High Income .....	278
Oceania .....	282
Sub-saharan africa, central .....	283
Sub-saharan africa, east.....	285
Sub-Saharan Africa, Southern.....	294
Sub-Saharan Africa, West.....	297

---

# Acknowledgements

The author acknowledges the help of:  
Dr. Chhavi Satish Nanda  
in all stages of literature review and the preparation of this document.

---

---

# Background

## Hepatitis E virus

Hepatitis E virus (HEV) is a small, non-enveloped virus, approximately 27-34 nm in diameter. The virus has a polyadenylated, single-stranded RNA genome, approximately 7.2 kilobases in length, with a positive polarity and a cap at its 5'-end. The viral genome contains short non-coding regions at both the 5' and the 3' ends, and contains three discontinuous and partially overlapping open reading frames. The largest open reading frame (ORF), known as ORF1, codes for viral non-structural proteins and contains several conserved domains, including putative methyltransferase, protease, helicase and RNA-dependent RNA polymerase. The ORF2 codes for the viral capsid protein, and the ORF3 for a small phosphoprotein with uncertain function. HEV is the only member of the genus *Hepevirus* and is placed in the family *Hepeviridae*.

The genus *Hepevirus* consists so far of two species: (i) mammalian HEV, which causes human disease and infects several other mammalian species, in particular pigs; and (ii) avian HEV, which is responsible for big liver and spleen disease in chicken, and is known to infect other birds such as turkeys. The avian HEV is believed not to be transmitted to man.

## *Viral genotypes*

On genomic sequence analysis, human and swine HEV isolates group into four genotypes, namely genotypes 1, 2, 3 and 4, each with several subtypes. Avian isolates of HEV have a shorter (6.6 kb) genome with only approximately 50% sequence homology with mammalian isolates. These isolates thus constitute a genetically distinct group, which though initially proposed to be a fifth HEV genotype, appears to be a separate genus. All HEV genotypes share at least one major, serologically cross-reactive epitope and belong to a single serotype. Each HEV genotype appears to have a specific

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29102](https://www.yunbaogao.cn/report/index/report?reportId=5_29102)

